Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor

Cell Growth and Differentiation

Volumn 9, Issue 1, 1998, Pages 49-58

  Lin, Pengnian ^a   Sankar, Sabita ^a   Shan, Si Qing ^a   Dewhirst, Mark W ^a   Polverini, Peter J ^b   Quinn, Timothy Q ^c   Peters, Kevin G ^a  

^a DUKE UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE RECEPTOR; RECOMBINANT VASCULOTROPIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; RAT; RECEPTOR AFFINITY; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANIMALS; CELL DIVISION; CELL MOVEMENT; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; RATS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT PROTEINS;

EID: 0031965353     PISSN: 10449523     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Folkman, J. What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst., 82: 4-6, 1990.
2. Hayes, D. F. Angiogenesis and breast cancer. Breast Cancer, 8: 51-71, 1994.
3. Liotta, L. A., Steeg, P. S., and Stetler-Stevenson, W. G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell, 64: 327-336, 1991.
4. Folkman, J., Watson, K., Ingber, D., and Hanahan, D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature (Lond.), 339: 58-64, 1989.
5. Kandel, J., Bossy-Wetzel, E., Radvanyi, F., Klagsbrun, M., Folkman, J., and Hanahan, D. Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell, 66: 1095-1104, 1991.
6. Ferrara, N., Houck, K. A., Jakeman, L. B., Winer, J., and Leung, D. W. The vascular endothelial growth factor family of polypeptides. J. Cell Biochem., 47: 211-218, 1991.
7. Connolly, D. T. Vascular permeability factor a unique regulator of blood vessel function. J. Cell Biochem., 47: 219-223, 1991.
8. Vaisman, N., Gospodarowicz, D., and Neufeld, G. Characterization of the receptor for vascular endothelial growth factor. J. Biol. Chem., 265: 19461-19466, 1990.
9. De Vries, C., Escobedo, J. A., Ueno, H., Kouck, K., Ferrara, N., and Williams, L. T. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science (Washington DC), 255: 989-991, 1992.
10. Terman, B. I., Dougher-Vermazen, M., Carrion, M. E., Dimitrov, D., Armellino, D. C., Gospodarowicz, D., and Bohlen, P. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem. Biophys. Res. Commun., 187: 1579-1586, 1992.
11. Shibuya, M. Role of VEGF-flt receptor system in normal and tumor angiogenesis. Adv. Cancer Res., 67: 281-316, 1995.
12. Fong, G-H., Rossant, J., Gertsenstein. M., and Breitman, M. L. Role of Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature (Lond.), 376: 66-69, 1995.
13. Shalaby, F., Rossant, J., Yamaguchi, T. P., Gertsenstein, M., Wu, X-F., Breitman, M. L., and Schuh, A. C. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature (Lond.), 376: 62-65, 1995.
14. Brown, L. F., Berse, B., Jackman, R. W., Tognazzi, K., Guidi, A. J., Dvorak, H. F., Senger, D. R., Connolly, J. L., and Schnitt, S. J. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum. Pathol., 26: 86-91, 1995.
15. Brown, L. F., Berse, B., Jackman, R. W., Tognazzi, K., Manseau, E. J., Senger, D. R., and Dvorak, H. F. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res., 53: 4727-4735, 1993.
16. Easty, D. J., Herlyn, M., and Bennett, D. C. Abnormal protein tyrosine kinase gene expression during melanoma progression and metastasis. Int. J. Cancer, 60: 129-136, 1995.
17. Hatva, E., Kaipainen, A., Mentula, P., Jaaskelainen, J., Paetau, A., Haltia, M., and Alitato, K. Expression of endothelial cell-specific receptor tyrosine kinases and growth factors in human brain tumors. Am. J. Pathol., 146: 368-378, 1995.
18. Plate, K. H., Breier, G., Weich, H. A., Mennel, H. D., and Risau, W. Vascular growth factor and glioma angiogenesis: coordinate induction of VEGF receptors distribution of VEGF protein and possible in vivo regulatory mechanisms. Int. J. Cancer, 59: 520-529, 1994.
19. Takahaski, A., Sasaki, H., Kim, S. J., Tobisu, K. I., Kakizoe, T., Tsukamoto, T., Kumamoto, Y., Sugimura, T., and Terada, M. Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res., 54: 4233-4237, 1994.
20. Warren, R. S., Yuan, H., Matli, M. R., Gillett, N. A., and Ferrara, N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J. Clin. Invest., 95: 1789-1797, 1995.
21. Zhang, H-T., Craft, P., Scott, P. A. E., Ziche, M., Weich, H. A., Harris, A. L., and Bicknell, R. Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells. J. Natl. Cancer Inst., 87: 213-219, 1995.
22. Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Philips, H. S., and Ferrara, N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature (Lond.), 362: 841-844, 1993.
23. Millauer, B., Longhi, M. P., Plate, K. H., Shawver, L. K., Risau, W., Ullrich, A., and Strawn, L. M. Dominant-negative inhibition of flk-1 suppresses the growth of many tumor types in vivo. Cancer Res., 56: 1615-1620, 1996.
24. Sporeno, E., Barbato, G., Graziani, R., Pucci, P., Nitti, G., and Paonessa, G. Production and structural characterization of amino terminally histidine tagged human oncostatin M in E. coli. Cytokine, 6: 255-264, 1994.
25. Chen, X-S., Brash, A. R., and Funk, C. D. Purification and characterization of recombinant histidine-tagged human platelet 12-lipoxygenase expressed in a baculovirus/insect cell system. Eur. J. Biochem., 214: 845-852, 1993.
26. + +NTA affinity chromatography. FEES Lett., 363: 148-150, 1995.
27. Polverini, P. J., Bouck, N. P., and Rastinejad, F. Assay for purification of naturally occurring inhibitors of angiogenesis. Methods Enzymol., 198: 440-450, 1991
28. Dewhirst, M. W., Vinuya, R. Z., Ong, E. T., Klitzman, B., Rosner, G., Secomb, T. W., and Gross, J. F. Effects of bradykinin on the hemodynamics of tumor and granulating normal tissue microvasculature. Radiat. Res., 130: 345-354, 1992.
29. Folkman, J. Angiogenesis in cancer, vascular rheumatoid and other diseases. Nat. Med., 1: 27-30, 1995
30. Takahashi, Y., Kitadai, Y., Bucana, C. D., Cleary, K. R., and Ellis, L. M. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res., 55: 3964-3968, 1995.
31. Weidner, N., Semple, J. P., Welch, W. R., and Folkman, J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N. Engl. J. Med., 324: 1-8, 1991.
32. Khazaeli, M. B., Conry, R. M., and LoBuglio, A. F. Human immune response to monoclonal antibodies. J. Immunol., 15: 42-52, 1994.
33. Goldenberg, D. M. New developments in monoclonal antibodies for cancer detection and therapy. CA Cancer J. Clin., 44: 43-64, 1994.
34. Strawn, L. M., McMahon, G., App, H., Schreck, R., Kuchler, W. R., Longhi, M. P., Hui, T. H., Tankg, C., Levitzki, A., Gazit, A., Chen, I., Keri, G., Orfi, L., Risan, W., Flamme, I., Ullrich, A., Hirth, K. P., and Shawver, L. K. Flk-1 as a target for tumor growth inhibition. Cancer Res., 56: 3540-3545, 1996.
35. Kendall, R. L., and Thomas, K. A. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc. Natl. Acad. Sci. USA, 90: 10705-10709, 1993.
36. Aiello, L. P., Pierce, E. A., Foley, E. D., Takagi, H., Chen, H., Riddle, L., Ferrara, N., King, G. L., and Smith, L. E. H. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc. Natl. Acad. Sci. USA, 92: 10457-10461, 1996.
37. Kendall, R. J., Wang, G., DiSalvo, J., and Thomas, K. A. Specificity of vascular endothelial cell growth factor receptor ligand binding domains. Biochem. Biophys. Res. Commun., 201: 326-330, 1994.
38. Duan, D-S., Pazin, M. J., Fretto, L. J., and Williams, L. T. A functional soluble extracellular region of the platelet-derived growth factor (PDGF) b-receptor antagonizes PDGF-stimulated responses. J. Biol. Chem., 266: 413-418, 1991.
39. Ganser, A., Maurer, A., Contzen, C., Seipelt, G., Ottmann, O. G., Schadeck-Gressel, C., Kolbe, K., Haas, R., Zander, C., Reutzel, R., and Hoelzer, D. Improved multilineage response of hematopoiesis in patients with myelodysplastic syndromes to a combination therapy with all-trans-retinoic acid, granulocyte colony-stimulating factor, erythropoietin and alpha-tocopherol. Ann. Hematol., 72: 237-244, 1996.
40. Fontijn, R., Hop, C., Brinkman H. J., Slater, R., Westerveld, A., van Mourik, J. A., and Pannekock, H. Maintenance of vascular endothelial cell-specific properties after immortalization with an amphotrophic replication-deficient retrovirus containing human papilloma virus 16E6/E7 DNA. Exp. Cell Res., 216: 199-207, 1995.
41. 131I-labelled anti-tenasin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies. Cancer Res., 49: 2807-2813, 1989.
42. Clyman, R. I., Peters, K. G., Chen, Y-Q., Escobedo, J., Williams, L. T., Ives, H. E., and Wilson. E. Phospholipase C gamma activation, phosphotidylinositol hydrolysis, and calcium mobilization are not required for FGF receptor-mediated chemotaxis. Cell Adhesion Commun., 1: 333-342, 1994.
43. Papenfuss, D., Gross, J. F., Intaglitta, M., and Treese, F. A. A transparent access chamber for the rat dorsal skin fold. Microvasc. Res., 18: 311-318, 1979.